| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 44.8 | 30.5 | 30.8 |
| Other income | 0.7 | 0.1 | 0.1 |
| Total income | 45.5 | 30.6 | 30.9 |
| Profit before exceptional items & tax | 8.1 | 4.9 | 4.2 |
| Profit before tax | 8.1 | 4.9 | 4.2 |
| Net profit | 8.2 | 4.9 | 2.7 |
| Operating margin | 17.8% | 16.0% | 13.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +203.70% |
|---|---|
| Net profit, quarter on quarter | +67.30% |
| Revenue, year on year | +45.50% |
Source
Read the filing ↗
BSE results filing, BSE: 544738. Figures extracted from the filing.
Speciality Medicines Ltd: key numbers
- Share price
- ₹162.20
- Market cap
- ₹142.5 Cr
- Revenue (annual)
- ₹75.29 Cr
- Net profit (annual)
- ₹13.03 Cr
- P/E (TTM)
- 10.9×Sector 50.4×
- Promoter holding
- 43.43%
- FII holding
- 0.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Speciality Medicines Ltd
All →
19:45 IST
BSE
Annual Report
Speciality Medicines Annual Report
Speciality Medicines Limited has submitted its Annual Report for the financial year 2025-26 to the exchange, complying with regulatory filing requirements.
15:50 IST
BSE
Annual General Meeting
Speciality Medicines Annual General Meeting
Speciality Medicines Limited scheduled its 5th Annual General Meeting for September 28, 2026. The board also approved the draft Directors' Report for FY 2025-26.